Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: A hellenic cooperative oncology group (HeCOG) study

European Journal of Epidemiology

Volumn 27, Issue 11, 2012, Pages 857-866

  Panagopoulou, Paraskevi ^a   Gogas, Helen ^a   Dessypris, Nick ^a   Maniadakis, Nikos ^b   Fountzilas, George ^c   Petridou, Eleni Th ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Breast cancer; Healthcare access; Healthcare inequalities; Obesity; Prognosis; Socioeconomic status (SES); Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); FEMALE; GEOGRAPHIC DISTANCE; GEOGRAPHY; GREECE; HEALTH CARE ACCESS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OBESITY; RISK FACTOR; TERTIARY HEALTH CARE; TRAVEL; TRAVEL TIME; TUMOR VOLUME;

ADULT; AGED; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; GREECE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OBESITY; PROGNOSIS; RESIDENCE CHARACTERISTICS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TERTIARY HEALTHCARE; TRAVEL;

EID: 84871339514     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-012-9737-z     Document Type: Article

References (58)

1. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309-30.
2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 366(9503):2087-106. doi:10.1016/S0140-6736(05)67887-7.
3. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245-62. doi:10.1677/erc-10-0136.
4. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. AnnOncol. 2006;17(10):1504-11. doi:10.1093/annonc/mdl147.
5. Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008; 123(9):2188-94.
6. Hellmann SS, Thygesen LC, Tolstrup JS, Gronbaek M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: Results from a prospective cohort study. Eur J Cancer Prevent. 2010;19(5):366-73. doi:10.1097/CEJ.0b013e32 833b4828.
7. Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, et al. Greater Survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25(17):2345-51. doi: 10.1200/jco.2006.08.6819.
8. Parkin DM, Boyd L. Cancers attributable to overweight and obesity in the UK in 2010. Br J Cancer. 2011;105(S2):S34-7.
9. Protani M, Coory M, Martin J. Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627-35.
10. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience. Ann Oncol. 2004;15(6):875-84. doi:10.1093/ annonc/mdh222.
11. Barnett GC, Shah M, Redman K, Easton DF, Ponder BAJ, Pharoah PDP. Risk factors for the incidence of breast cancer: Do they affect survival from the disease? J Clin Oncol. 2008;26(20): 3310-6. doi:10.1200/jco.2006.10.3168.
12. Ewertz M, Jensen M-B, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after earlystage breast cancer. J Clin Oncol. 2010;29(1):25-31. doi:10.1200/ jco.2010.29.7614.
13. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1871-7. doi:10.1158/1055-9965. epi-06-0356.
14. Dignam JJ, Mamounas EP. Obesity and breast cancer prognosis: An expanding body of evidence. Ann Oncol. 2004;15(6):850-1. doi:10.1093/annonc/mdh241.
15. Bouchardy C, Verkooijen HM, Fioretta G. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer. 2006;119(5):1145-51.
16. Dalton SO, Ross L, During M, Carlsen K, Mortensen PB, Lynch J, et al. Influence of socioeconomic factors on survival after breast cancer-a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983-1999. Int J Cancer. 2007; 121(11):2524-31.
17. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94(7):490-6. doi:10.1093/jnci/94.7.490.
18. Yu X. Socioeconomic disparities in breast cancer survival: Relation to stage at diagnosis, treatment and race. BMC Cancer. 2009;9(1):364.
19. McGinnis JM, Williams-Russo P, Knickman Jr. The case for more active policy attention to health promotion. Health Aff. 2002;21(2):78-93. doi:10.1377/hlthaff.21.2.78.
20. Probst J, Laditka S, Wang J-Y, Johnson A. Effects of residence and race on burden of travel for care: Cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Services Res. 2007;7(1):40.
21. Zgibor JC, Gieraltowski LB, Talbott EO, Fabio A, Sharma RK, Karimi H. The association between driving distance and glycemic control in rural areas. J Diabetes Sci Technol. 2011;5(3):494-500.
22. Scoggins JF, Fedorenko CR, Donahue SMA, Buchwald D, Blough DK, Ramsey SD. Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health. 2011; Article first published online: 31 Mar 2011. doi:10.1111/j.1748-0361.2011.00371.x.
23. Dejardin O, Remontet L, Bouvier AM, Danzon A, Tretarre B, Delafosse P, et al. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. Br J Cancer. 2006;95(7):944-9.
24. Crawford SM, Sauerzapf V, Haynes R, Zhao H, Forman D, Jones AP. Social and geographical factors affecting access to treatment of lung cancer. Br J Cancer. 2009;101(6):897-901.
25. Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92(3):269-71. doi:10.1093/jnci/92.3.269.
26. JonesAP,Haynes R, SauerzapfV,Crawford SM, ZhaoH, Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer. 2008;44(7):992-9.
27. Baird G, Flynn R, Baxter G, Donnelly M, Lawrence J. Travel time and cancer care: An example of the inverse care law? Rural Remote Health. 2008;8(4):1003 (Online). Epub Nov 13, 2008.
28. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed byCMF with or without paclitaxel, in patients with high-risk operable breast cancer: A randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16(11):1762-71. doi:10.1093/annonc/mdi366.
29. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: Safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19(5):853-60. doi:10.1093/annonc/mdm539.
30. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat. 2011;2011 Dec 21. [Epub ahead of print] doi: 10.1007/s10549-011-1913-4.
31. Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and Weekly paclitaxel in patients with resected high-risk breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study. Cancer Invest. 2008;26(5):491-8. doi:10.1080/07357900701829785.
32. Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papakostas P, et al. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol. 2006;23(4):479-88.
33. Acock AC. Working with missing values. J Marriage Fam. 2005; 67:1012-28.
34. Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley; 1987.
35. Meden T, St. John-Larkin C, Hermes D, Sommerschield S. Relationship between travel distance and utilization of breast cancer treatment in rural northern michigan. JAMA. 2002;287(1):111. doi:10.1001/jama.287.1.111.
36. Celaya M, Rees J, Gibson J, Riddle B, Greenberg E. Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control. 2006;17(6):851-6.
37. Ahamad A. Geographic access to cancer care: A disparity and a solution. Postgrad Med J. 2011;87(1031):585-9. doi:10.1136/pgmj.2010.111930.
38. Wan Y. Examine the effect of geographic distance on breast cancer patients' utilization of high volume hospitals [Master of Science Thesis]. Iowa. University of Iowa; 2009. http://ir.uiowa. edu/etd/446.
39. Wee C, McCarthy E, Davis R, Phillips R. Screening for cervical and breast cancer: Is obesity an unrecognized barrier to preventive care? Ann Intern Med. 2000;132(9):697-704.
40. Mitchell KJ, Fritschi L, Reid A, McEvoy SP, Ingram DM, Jamrozik K, et al. Rural-urban differences in the presentation, management and survival of breast cancer in Western Australia. Breast. 2006;15(6):769-76. doi:10.1016/j.breast. 2006.04.001.
41. Gulliford M, Figueroa-Munoz J, Morgan M, Hughes D, Gibson B, Beech R, et al. What does 'access to health care' mean? J Health Serv Res Policy. 2002;7(3):186-8. doi:10.1258/1355819 02760082517.
42. OECD. Regions at a glance 2007. Regional disparities in GDP per capita. 2007. p. 58-3. Available from: Www.sourceoecd.org/ governance/9789264009875.
43. Charalampopoulou A, Petridou E, Spyridopoulos T, Dessypris N, Oikonomou A, Athanasiadou-Piperopoulou F, et al. An integrated evaluation of socioeconomic and clinical factors in the survival from childhood acute lymphoblastic leukaemia: A study in Greece. Eur J Cancer Prev. 2004;13(5):397-401.
44. Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: The impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263-9.
45. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: A review. JWomens Health (Larchmt). 2009;18(6):883-93. doi:10.1089/jwh.2008.1127.
46. Loi S, Milne RL, Friedlander ML, McCredie MRE, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1686-91. doi:10.1158/1055-9965.epi- 05-0042.
47. Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, et al. Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158(10):963-8. doi:10.1093/aje/kwg236.
48. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002; 13(4):325-32.
49. Hall HI, Coates RJ, Uhler RJ, Brinton LA, Gammon MD, Brogan D, et al. Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer. 1999;82(1):23-7.
50. Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267-73. doi:10.1001/archinte.165.11.1267.
51. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003;21(10):1961-6.
52. Maehle B, Tretli S. Pre-morbid body-mass-index in breast cancer: Reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat. 1996;41(2):123-30.
53. Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T, et al. editors [S2-1]. Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer. 33rd Annual San Antonio Breast Cancer Symposium; 2010; San Antonio, Texas, USA.
54. Ademuyiwa FO, GromanA,O'Connor T,AmbrosoneC,Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triplenegative breast cancer. Cancer. 2011;117(18):4132-40.
55. Parolin V, Fiorio E, Mercanti A, Riolfi M, Cetto GL, Surmacz E, et al. Impact of BMI on clinical outcome of HER2-positive breast cancer. J Clin Oncol. 2010;28:15s(suppl;abstr 1130).
56. Goodwin PJ. Insulin in the adjuvant breast cancer setting: A novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol. 2008;26(6):833-4. doi:10.1200/jco.2007.14.7132.
57. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-i, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48-60. doi:10.1093/jnci/djn415.
58. Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler D. Health effects of financial crisis: Omens of a Greek tragedy. Lancet. 2011;378(9801):1457-8.